CVS Earnings Beat Estimates, Stock Price Heading Higher

Steve Miller
cvs stock price higher forecast earnings report strong february 13

CVS (stock ticker: CVS) Weekly Chart Grid

CVS reported earnings that broadly beat the street’s estimates on Wednesday, February 12.

CVS reported adjusted EPS of $1.73, which beat estimates of $1.68. The company reported revenue of $66.9B, which also beat estimates of $63.97B.

The company forecasted annual EPS from $7.04 – $7.17 in 2020, which was in-line with analyst expectations of $7.15.

Let’s discuss what the stock chart is telling us.

$CVS Technical Briefing

See the CVS stock chart above for reference. The weekly cycle analysis suggests that CVS formed an important cyclical base and is in a very positive intermediate-term pattern. Weekly momentum is negative.

On the upside, there is an intermediate-term Fibonacci confluence zone from 79.19 – 82.71. On the downside, there is an intermediate-term support zone from 70.58 – 68.58. For the bears to regain control of the intermediate-term, we would likely need to see a weekly close below cycle low support at 66.79

cvs stock investment technical price indicators bullish bearish chart image february 13

$CVS Sum of the Evidence

CVS is in a very bullish intermediate-term cycle pattern with negative momentum. Given these conditions, we would expect short-term sell-offs to be limited to the intermediate Fibonacci support zone beginning at 70.58. There is a likelihood the stock tests 79 by May.

At askSlim we use technical analysis to evaluate price charts of stocks, futures, and ETF’s. We use a combination of cycle, trend and momentum chart studies, on multiple timeframes, to present a “sum of the evidence” directional outlook in time and price.

Interested in askSlim?

Get professional grade technical analysis, trader education and trade planning tools at askSlim.com. Write to matt@askslim.com and mention See It Market in your email for special askSlim membership trial offers!

Twitter:  @askslim

Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.

NOT INVESTMENT ADVICE – PLEASE READ INVESTMENT DISCLAIMER.